Tilray Brands, Inc. (NASDAQ:TLRY) Quarterly Earnings Preview

  • Earnings Per Share (EPS) is expected to be -$0.03, marking a 25% improvement year-over-year.
  • Revenue projections stand at approximately $233.3 million, indicating a 4.4% increase from the previous year.
  • Financial ratios reveal challenges in profitability and cash flow, but a strong liquidity position with a current ratio of 2.62.

Tilray Brands, Inc. (NASDAQ:TLRY) is a prominent player in the cannabis industry, known for its diverse range of cannabis products. The company operates in a competitive market alongside other major cannabis firms. As TLRY prepares to release its quarterly earnings on July 28, 2025, investors are keenly watching the anticipated financial results.

Wall Street estimates that TLRY will report an earnings per share (EPS) of -$0.03. This represents a 25% improvement from the same period last year, as highlighted by the company's expected quarterly loss. Despite the negative EPS, the improvement suggests that TLRY is making strides towards better financial health.

Revenue projections for TLRY are approximately $233.3 million, with some estimates reaching $240 million, indicating a 4.4% year-over-year increase. This growth in revenue reflects the company's efforts to expand its market presence and increase sales, even as the cannabis industry faces various challenges.

The stability in the consensus EPS estimate over the past 30 days suggests that analysts have maintained their initial projections. This stability is important as revisions to earnings estimates can influence investor behavior and impact short-term stock price movements.

TLRY's financial ratios provide insight into its current financial position. The company has a price-to-earnings (P/E) ratio of -0.68, indicating it is not yet profitable. However, a price-to-sales ratio of 0.88 suggests the stock is valued at less than one times its sales, which may appeal to value investors. The enterprise value to sales ratio of 1.06 and the enterprise value to operating cash flow ratio of -17.24 highlight challenges in generating positive cash flow. Despite these challenges, TLRY maintains a strong liquidity position with a current ratio of 2.62, indicating its ability to cover short-term liabilities.
Tilray Brands, Inc. View
Symbol Price %chg
SIDO.JK 520 -0.96
TSPC.JK 2160 0.93
000105.KS 103100 -0.58
000100.KS 111000 -0.9
TLRY Ratings Summary
TLRY Quant Ranking
Related Analysis

Tilray Brands, Inc. (NASDAQ:TLRY) Insider Buying and Financial Overview

  • The Chief Financial Officer of Tilray Brands, Inc. (NASDAQ:TLRY) demonstrates confidence in the company by purchasing 33,500 shares.
  • Tilray's financial metrics reveal a mixed picture with a strong liquidity position but challenges in generating positive cash flow.
  • The company's strategic initiatives and financial management are crucial in maintaining its competitive position in the cannabis industry.

Tilray Brands, Inc. (NASDAQ:TLRY) is a prominent player in the cannabis industry, known for its diverse range of cannabis products. The company operates globally, focusing on medical and recreational cannabis, as well as hemp-based foods and beverages. Tilray competes with other major cannabis companies like Canopy Growth and Aurora Cannabis, striving to maintain its market position through strategic initiatives and financial management.

On July 30, 2025, Merton Carl A, the Chief Financial Officer of Tilray, made a significant move by purchasing 33,500 shares of the company's common stock at approximately $0.60 each. This transaction increased his total ownership to 798,069 shares. Such insider buying can often signal confidence in the company's future prospects, despite the challenges highlighted in recent financial discussions.

During Tilray's Q4 2025 earnings conference call, key executives, including Merton Carl A, discussed the company's financial performance and strategic direction. The call, held on July 28, 2025, attracted attention from analysts at Alliance Global Partners and ATB Capital Markets Inc., reflecting the investment community's keen interest in Tilray's operations and future plans.

Tilray's financial metrics present a mixed picture. The company has a price-to-sales ratio of 0.77 and an enterprise value to sales ratio of 0.79, indicating a relatively low valuation compared to its sales. The debt-to-equity ratio is 0.16, showing a conservative approach to debt. However, the negative price-to-earnings ratio and earnings yield suggest ongoing financial losses.

Despite these challenges, Tilray maintains a strong liquidity position with a current ratio of 2.46, meaning it has more than twice the current assets compared to its current liabilities. However, the negative enterprise value to operating cash flow ratio highlights difficulties in generating positive cash flow from operations, a critical area for the company's financial health.

Tilray Brands, Inc. (NASDAQ:TLRY) Fiscal Year 2025 Financial Highlights

  • Net revenue of $821 million for fiscal year 2025, with a constant currency revenue of $834 million.
  • International cannabis revenue surged by 71% in Q4 and 19% for the fiscal year.
  • Adjusted EBITDA expected to range between $62 million and $72 million for fiscal year 2026.
Tilray Brands, Inc. (NASDAQ:TLRY) is a prominent player in the cannabis industry, known for its diverse portfolio that spans cannabis, beverages, and wellness products. The company reported a net revenue of $821 million for fiscal year 2025, with a constant currency revenue of $834 million. Despite a $13 million revenue impact from strategic initiatives and SKU rationalization in the fourth quarter, Tilray achieved its second-highest consolidated adjusted EBITDA in history during the period.Tilray's international cannabis revenue surged by 71% in Q4 and 19% for the fiscal year, with European cannabis revenue increasing by 112% when excluding Australia.
 
The company expanded its beer presence in the U.S. by acquiring four craft brands from Molson Coors and launched Project 420 to integrate its craft beer businesses. Additionally, Tilray introduced hemp-derived Delta-9 THC drinks in the U.S., reaching 1,300 distribution points across 13 states.The beverage segment experienced a 19% revenue growth, reaching $241 million, while the wellness segment grew by 9% to $60 million.
 
Tilray maintains a strong balance sheet with $256 million in cash and marketable securities, having repaid approximately $100 million in total debt. The company is leveraging AI to enhance efficiency and growth, particularly in its global greenhouse operations.Despite a net loss of $30.9 million, or -$0.038 per share on an adjusted basis, in the fourth quarter, primarily due to operational challenges and strategic adjustments, Tilray remains optimistic about future growth. For fiscal year 2026, the company expects adjusted EBITDA to range between $62 million and $72 million, with a focus on expanding its global supply chain and cultivation footprint.

Tilray Brands, Inc. (NASDAQ:TLRY) Overview and Analyst Insights

Tilray Brands, Inc. (NASDAQ:TLRY) is a prominent player in the cannabis industry, known for its production and distribution of medical and recreational cannabis products. The company operates globally, with a focus on innovation and strategic partnerships to expand its market reach. Tilray faces competition from other cannabis companies like Canopy Growth and Aurora Cannabis, which also aim to capture market share in this rapidly growing industry.

On July 29, 2025, Kaumil Gajrawala from Jefferies set a price target of $1.50 for Tilray. At that time, the stock was priced at $0.5769, indicating a significant potential upside of approximately 40% from the target. This optimistic outlook suggests confidence in Tilray's future performance, despite the current stock price reflecting a decrease of 17.55%, with a change of -$0.12.

During Tilray's Q4 2025 earnings conference call, key figures like CEO Irwin David Simon and CFO Carl A. Merton discussed the company's financial performance and strategic direction. Analysts such as Aaron Thomas Grey and Frederico Yokota Choucair Gomes participated, likely focusing on Tilray's market strategies and future outlook. This discussion is crucial for understanding the company's position in the cannabis industry.

The stock for TLRY has shown volatility, with a daily range between $0.55 and $0.62. Over the past year, it reached a high of $2.15 and a low of $0.35. This fluctuation reflects the challenges and opportunities in the cannabis market. Despite these challenges, Tilray's market capitalization remains at approximately $598.9 million, indicating its substantial presence in the industry.

With a trading volume of 70,960,280 shares on the NASDAQ exchange, Tilray continues to attract investor interest. The company's strategic initiatives and market positioning are key factors that could influence its stock performance. As highlighted by StreetInsider, Jefferies' reiterated buy rating underscores the potential for growth and value in Tilray's stock.

Tilray Brands, Inc. (NASDAQ:TLRY) Overview and Financial Performance

Tilray Brands, Inc. (NASDAQ:TLRY) is a prominent player in the cannabis industry, known for its production and distribution of medical and recreational cannabis products. The company operates globally, with a focus on expanding its market presence and product offerings. Tilray faces competition from other cannabis companies like Canopy Growth and Aurora Cannabis, which also aim to capture market share in this rapidly growing industry.

On July 29, 2025, Jefferies reiterated its "Buy" rating for Tilray, maintaining a positive outlook on the stock. Despite the "Buy" rating, the action was marked as "hold," indicating a cautious approach. At the time, TLRY was priced at approximately $0.58, reflecting a slight decrease from its current price of $0.57. This price change represents a 17.55% decline, with a decrease of $0.12.

Tilray's recent Q4 2025 earnings conference call, held on July 28, 2025, provided valuable insights into the company's financial performance and strategic direction. Key company figures, including CEO Irwin David Simon and CFO Carl A. Merton, participated in the call. Analysts from Alliance Global Partners and ATB Capital Markets Inc. also joined, highlighting the importance of the event for investors and stakeholders.

The stock's trading range today has been between a low of $0.55 and a high of $0.62, indicating some volatility. Over the past year, TLRY has experienced significant fluctuations, with a high of $2.15 and a low of $0.35. This volatility is not uncommon in the cannabis industry, where regulatory changes and market dynamics can impact stock prices.

Tilray's market capitalization currently stands at approximately $598.9 million, reflecting its position in the industry. The trading volume for TLRY is substantial, with 70,960,280 shares traded on the NASDAQ exchange. This high trading volume suggests active investor interest and engagement with the stock, despite its recent price decline.

Tilray Brands, Inc. (NASDAQ:TLRY) Faces Financial Challenges Despite Strong Market Presence

  • Tilray Brands, Inc. (NASDAQ:TLRY) reported an earnings per share (EPS) of -$0.87, significantly missing the estimated EPS of -$0.04.
  • The company's revenue for the fiscal third quarter was $185.78 million, falling short of the estimated $267.87 million.
  • Despite financial challenges, Tilray maintains a price-to-sales ratio of approximately 0.52 and a current ratio of approximately 2.54.

Tilray Brands, Inc. (NASDAQ:TLRY) is a prominent player in the cannabis industry, known for its diverse product offerings, including medical and recreational cannabis, hemp-based foods, and beverages. The company operates in a competitive market alongside other cannabis giants like Canopy Growth and Aurora Cannabis. Despite its strong market presence, Tilray faces financial challenges, as reflected in its recent earnings report.

On April 8, 2025, Tilray reported an earnings per share (EPS) of -$0.87, significantly missing the estimated EPS of -$0.04. This disappointing performance was discussed during the company's Q3 2025 earnings conference call, which included key executives like Irwin Simon, CEO, and Carl Merton, CFO. Analysts from firms such as Alliance Global Partners and TD Securities participated, highlighting the market's keen interest in Tilray's financial health.

Tilray's revenue for the fiscal third quarter was $185.78 million, falling short of the estimated $267.87 million. This revenue decline, from $188.3 million the previous year, contributed to a 16% drop in the company's share price, as highlighted by Proactive Investors. The underperformance in revenue has led to investor disappointment and a sharp decline in Tilray's stock value.

Despite these challenges, Tilray maintains a price-to-sales ratio of approximately 0.52, indicating that the market values its sales at about half of its current market price. The enterprise value to sales ratio is around 0.74, suggesting a slightly higher total valuation, including debt. The company's debt-to-equity ratio is relatively low at 0.11, reflecting a conservative use of debt.

Tilray's liquidity position remains strong, with a current ratio of approximately 2.54, indicating it has more than twice the current assets compared to its current liabilities. However, the company faces financial challenges, as evidenced by its negative earnings yield and negative price-to-earnings ratio. These metrics suggest that Tilray is experiencing difficulties in generating profits, which may impact its future financial performance.

Tilray Brands, Inc. (NASDAQ:TLRY) Faces Financial Challenges Despite Strong Market Presence

  • Tilray Brands, Inc. (NASDAQ:TLRY) reported an earnings per share (EPS) of -$0.87, significantly missing the estimated EPS of -$0.04.
  • The company's revenue for the fiscal third quarter was $185.78 million, falling short of the estimated $267.87 million.
  • Despite financial challenges, Tilray maintains a price-to-sales ratio of approximately 0.52 and a current ratio of approximately 2.54.

Tilray Brands, Inc. (NASDAQ:TLRY) is a prominent player in the cannabis industry, known for its diverse product offerings, including medical and recreational cannabis, hemp-based foods, and beverages. The company operates in a competitive market alongside other cannabis giants like Canopy Growth and Aurora Cannabis. Despite its strong market presence, Tilray faces financial challenges, as reflected in its recent earnings report.

On April 8, 2025, Tilray reported an earnings per share (EPS) of -$0.87, significantly missing the estimated EPS of -$0.04. This disappointing performance was discussed during the company's Q3 2025 earnings conference call, which included key executives like Irwin Simon, CEO, and Carl Merton, CFO. Analysts from firms such as Alliance Global Partners and TD Securities participated, highlighting the market's keen interest in Tilray's financial health.

Tilray's revenue for the fiscal third quarter was $185.78 million, falling short of the estimated $267.87 million. This revenue decline, from $188.3 million the previous year, contributed to a 16% drop in the company's share price, as highlighted by Proactive Investors. The underperformance in revenue has led to investor disappointment and a sharp decline in Tilray's stock value.

Despite these challenges, Tilray maintains a price-to-sales ratio of approximately 0.52, indicating that the market values its sales at about half of its current market price. The enterprise value to sales ratio is around 0.74, suggesting a slightly higher total valuation, including debt. The company's debt-to-equity ratio is relatively low at 0.11, reflecting a conservative use of debt.

Tilray's liquidity position remains strong, with a current ratio of approximately 2.54, indicating it has more than twice the current assets compared to its current liabilities. However, the company faces financial challenges, as evidenced by its negative earnings yield and negative price-to-earnings ratio. These metrics suggest that Tilray is experiencing difficulties in generating profits, which may impact its future financial performance.